Literature DB >> 1662624

Spectrum of activity of azithromycin.

J D Williams1.   

Abstract

In recent years, a number of newer macrolides have been developed. One such antibiotic is azithromycin, which has a 15-membered ring structure and is classed as an azalide. The limitations of erythromycin and the discovery of pathogenic bacteria such as Campylobacter, Legionella and Chlamydia species provide incentives to study the usefulness of newer antibiotics of this class. Azithromycin has good activity against staphylococci, streptococci, Moraxella catarrhalis and other rapidly growing pyogenic bacteria. The good activity of azithromycin against Haemophilus influenzae (MIC90 0.5 mg/l) is particularly important as erythromycin has only marginal activity against this organism. Azithromycin has also been shown to be more potent than the macrolides against Enterobacteriaceae. In common with erythromycin and tetracycline, the agent has good activity against Legionella, Chlamydia and Campylobacter. Opportunistic infections involving Toxoplasma gondii and Pneumocystis carinii are an increasing problem and azithromycin is particularly interesting in view of its activity against these difficult-to-treat organisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662624     DOI: 10.1007/bf01975833

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

3.  In-vitro activity of erythromycin, roxithromycin and CP 62993 against common paediatric pathogens.

Authors:  S C Aronoff; C Laurent; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

4.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

5.  In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against Salmonella typhi.

Authors:  B Metchock
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.

Authors:  F W Goldstein; M F Emirian; A Coutrot; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Azithromycin in the treatment of sexually transmitted disease.

Authors:  O Steingrimsson; J H Olafsson; H Thorarinsson; R W Ryan; R B Johnson; R C Tilton
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

9.  In vitro activity of azithromycin against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

10.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more
  11 in total

1.  Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.

Authors:  S Jaruratanasirikul; R Hortiwakul; T Tantisarasart; N Phuenpathom; S Tussanasunthornwong
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  I Herrera-Insúa; P Pérez; C Ramos; P Martínez; M L Gómez-Lus; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 3.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors:  D A Stamler; M A Edelstein; P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin.

Authors:  T O'Reilly; S Kunz; E Sande; O Zak; M A Sande; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 7.  The new macrolides. Azithromycin and clarithromycin.

Authors:  M S Kanatani; B J Guglielmo
Journal:  West J Med       Date:  1994-01

8.  The use of macrolides in respiratory tract infections.

Authors:  J C Pechère
Journal:  Int J Antimicrob Agents       Date:  1993-11       Impact factor: 5.283

Review 9.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

10.  Azithromycin oral suspension in prevention and management of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a randomized controlled trial.

Authors:  Sayeh Parkhideh; Mohadeseh Zeraatkar; Omid Moradi; Abbas Hajifathali; Mahshid Mehdizadeh; Maria Tavakoli-Ardakani
Journal:  Support Care Cancer       Date:  2021-07-14       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.